[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100370520":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":62,"collaborators":18,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":18,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":18,"enrollmentInfo":73,"targetDuration":18,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":43,"whyStopped":18,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Sclnow Biotechnology Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"treatment group A （with mesenchymal stem cell intervention）","EXPERIMENTAL","observe the effectiveness and safety of patients by injecting human umbilical cord mesenchymal stem cells(2\\*10\\^7\u002Fml normal saline) and Low temperature plasma vaporization ablation",[13],"Biological: human umbilical cord mesenchymal stem cell",{"label":15,"type":16,"description":17,"interventionNames":18},"control group B","NO_INTERVENTION","observe the effectiveness and safety of patients by injecting normal saline and Low temperature plasma vaporization ablation",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"BIOLOGICAL","human umbilical cord mesenchymal stem cell","2\\*10\\^7",[9],[26],{"name":27,"affiliation":28,"role":29},"Yuanzhang Tang, Doctor","Xuanwu Hospital, Beijing","STUDY_DIRECTOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},"Jiaxiang Ni, Master","CONTACT","8613910743476","nijiaxiang@yahoo.com",{"name":37,"role":33,"phone":38,"phoneExt":18,"email":39},"Lei Guo, Doctor","861064368977","georgeguo@sclnow.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Xuanwu Hospital Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100053","China","CN",{"type":50,"coordinates":51},"Point",[52,53],116.39723,39.9075,{"lat":53,"lon":52},[56,58,59],{"name":32,"role":33,"phone":57,"phoneExt":18,"email":35},"13901743476",{"name":27,"role":33,"phone":18,"phoneExt":18,"email":18},{"name":60,"role":61,"phone":18,"phoneExt":18,"email":18},"Yaomin Liang","SUB_INVESTIGATOR",{"type":63,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100370520","phase-1-the-safetyefficacy-study-of-human-umbilical-cord-mesenchymal-stem-cells-therapy-19isclife-ldp-for-lumbar-discogenic-pain-100370520",false,"NCT04104412","The Safety\u002FEfficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-LDP) for Lumbar Discogenic Pain","The Safety\u002FEfficacy Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Lumbar Discogenic Pain","Inclusion Criteria:\n\n1. age over 18\n2. refractory and persistent lumbago pain for more than 6 months, with\u002Fwithout radiation pain in lower limbs, and poor conservative treatment effect;\n3. the straight leg elevation test was 70 degrees negative;\n4. MRI of lumbar spine showed herniated disc \\\u003C 6 mm, no obvious compression of spinal cord and nerve roots; T2-weighted mri of the lumbar spine showed decreased single\u002Fmulti-segment signal (black disc sign) or High signal zone (HIZ) in the posterior part of the intervertebral disc annulus.\n5. clinical signs of nerve localization were consistent with MRI changes;\n6. subject gives informed consent and signs informed consent.\n\nExclusion Criteria:\n\n1. coagulation dysfunction or anticoagulant therapy;\n2. intervertebral space infection, puncture site infection or systemic infection;\n3. lumbago pain of non-spinal origin, such as sacroiliac joint origin pain;\n4. patients who have had open surgery or other disc treatments;\n5. imaging examination suggested disc prolapse, prolapse, spinal canal bone stenosis, etc.;\n6. patients with vital organ system dysfunction and tumor lumbar vertebra metastasis;\n7. subjects with high tumor markers (AFP\u002FCEA\u002FCA199\u002FCA125);\n8. the subject is pregnant or breastfeeding;\n9. subjects also receive other treatments that may affect the efficacy and safety of stem cells;\n10. failing to control alcohol and other substance abuse during the 6 months prior to enrollment and enrollment period;\n11. the subjects suffer from mental illness, or lack of understanding, communication and cooperation, and cannot be guaranteed to follow the study protocol;\n\nSubjects who are not willing to sign informed consent and are participating in other clinical trials or have participated in other clinical trials within 3 months;","ALL","18 Years",{"count":74,"type":75},242,"ESTIMATED","INTERVENTIONAL",[78],"PHASE1","This experimental use umbilical cord mesenchymal stem cells in treatment of the early stage of lumbar discogenic pain (endogenous pain of the disc) to evaluate its safety and efficacy.\n\nThis experimental is mainly aimed at over 18years old people, regardless of gender, with refractory and persistent back pain for more than 6 months.\n\nThe efficacy and safety of mesenchymal stem cells (MSCS) were evaluated by low-temperature plasma ablation and intravertebral disc injection, which were divided into treatment group and control group.",[81],"Lumbar Discogenic Pain",[83,84],"lumbar discogenic pain","mesenchymal stem cell","2026-04-22",{"date":87,"type":88},"2026-04-23","ACTUAL",{"date":90,"type":88},"2019-08-15",{"date":92,"type":75},"2027-06-30",{"name":5,"class":6},1]